Overview

This trial is active, not recruiting.

Conditions chondromalacia, osteoarthritis, traumatic arthritis
Treatments cartizol, normal saline
Phase phase 4
Sponsor Sewon Cellontech Co., Ltd.
Start date April 2014
End date August 2015
Trial size 200 participants
Trial identifier NCT02539095, 01CTZ

Summary

The primary objective of this study is to confirm the superiority of intra-articular collagen injection in patients with knee joint pain compared to the control group. 100mm VAS is used to measure the pain of the subjects 24 weeks after the procedure.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, investigator)
Primary purpose treatment
Arm
(Experimental)
Their eligibility to participate in the study is checked, and they are randomized either into the intra-articular collagen injection group based on a randomization table.
cartizol Intra articular collagen injection
The product, CartiZol, which contains absorbable collagen, is applied on the cartilage defect to stimulate the neovasculization and cell penetration and to assist the natural wound healing process. It supplements the defective or damaged cartilage. Place the needle on the tip of the syringe and inject the product into the articular cavity.
(Placebo Comparator)
Their eligibility to participate in the study is checked, and they are randomized either into the (placebo) injection group based on a randomization table.
normal saline placebo
Supplementation of fluid and electrolytes (sodium or chlorine deficiency) Diluent for injection solution Place the needle on the tip of the syringe and inject the product into the articular cavity.

Primary Outcomes

Measure
Score change of 100 mm VAS
time frame: 24 weeks after injection

Secondary Outcomes

Measure
Score change of WOMAC (Western Ontario and McMaster Universities)
time frame: at the screening visit and then 4, 12, and 24 weeks after injection
Score change of SF-36 (36-ltem Short-Form Health Survey)
time frame: at the screening visit and then 4, 12, and 24 weeks after injection
Score change of Satisfaction evaluation by patients
time frame: at 4, 12, and 24 weeks after injection
Score change of Satisfaction evaluation by physician in charge
time frame: at 4, 12, and 24 weeks after injection
Score change of Physical examination
time frame: at the screening visit and then 4, 12, and 24 weeks after injection
Score change of 100 mm VAS
time frame: at the screening visit and then 4 and 12weeks after injection

Eligibility Criteria

Male or female participants at least 19 years old.

Inclusion Criteria: - 1. Adult patients aged 19 or older 2. Patients with knee joint pain due to chondromalacia, osteoarthritis (OA), or traumatic arthritis (TA) 3. Patients with 3 or lower score in the Kellgren-Lawrence grade 4. Patients with 40 mm or higher scores in the 100 mm VAS pain scale 5. Patients without significant pathological tests at their screening visit 6. Patients whose medication is confirmed within one week from their study enrolment and who agreed to maintain the medication dose during the study period if they need to keep taking it 7. When combination drugs are administered, considering the period of the drugs remaining in the body, patients who take the drugs stably for 2 weeks prior to participating in the trial (based on the screening, if it is confirmed that the patients took the drugs stably for 1 week prior to the screening, at the enrollment for injection, it should be assessed again, and the patients who are confirmed to have taken the drugs stably for 2 weeks prior to the trial could be registered). 8. Patients who, after taking drugs for anesthetic purposes (provided to the subject after the injection) within one week after the intra-articular injection, agreed to take anti-inflammatory agents for no more than 5 consecutive days and for no more than 10 days in a month, and could stop taking the drugs within 2 days after the next visit even if the pain in the observation site becomes severe and thus additional drugs are required. 9. Patients who agreed to use only the non-drug treatments (i.e., physiotherapy, osteopathy, and chiropractic therapy) allowed by the study investigators (Acupuncture is not allowed.) 10. Patients who agreed to receive the injection only in one knee when they feel pain on both knees (The other knee can be treated with prescribed drugs, but articular injections are not allowed.) 11. Patients or their representative (for adults) who agreed to participate in the study and signed the informed consent form Exclusion Criteria: - 1. Patients or their family members with a history of or an ongoing autoimmune disease 2. Patients with a history of anaphylactic response 3. Patients with hypersensitivity to grafting materials 4. Patients with hypersensitivity to porcine protein 5. Patient with grade 4 in the Kellgren-Lawrence grade 6. Patients with severe effusion 7. Patients who were injured severely or received injection in their affected knee within six months, which would make evaluation of the knee difficult 8. Patients with inflammatory arthritis such as rheumatoid arthritis, rupus arthrosis, or psoriatic arthritis 9. Patients who have gout or calcium pyrophosphate (pseudogout) disease that started within six months from the screening visit 10. Patients with a history of radiation therapy or cancer treatment within two years 11. Patients with diabetes 12. Patients with an infection that required hospitalization for antibiotics or the administration of antiseptic agents 13. Patients who have been undergoing adrenocortical hormone therapy 14. Patients with liver, heart, or kidney disease 15. Patients who had been infected with a virus 16. Patients who have a serious health condition that may affect the study results 17. Patients who are pregnant, breastfeeding, or planning to become pregnant 18. Patients who are considered inappropriate for participation in this study due to their condition (e.g., a mental illness) based on the investigator's judgment 8-15: The investigator can decide whether or not the patient will be administered the injection.

Additional Information

Official title A Double-blind, Randomized, Post-marketing Surveillance to Evaluate the Efficacy of Intra-articular Collagen Injection in Patients With Knee Joint Pain Compared to Normal Saline Injection
Principal investigator Young Wan Moon, MD
Description This study is a double-blind clinical trial. Two hundred subjects has participated in it. The study is explained to the subjects, and they voluntarily choose to participate in it. Their eligibility to participate in the study is checked, and they are randomized either into the intra-articular collagen injection group or the normal saline (placebo) injection group based on a randomization table. They are asked to follow the guidelines of the investigators during the study and to visit the hospital five times, including for screening. At each visit, the subjects will undergo an examination with doctors, a medical examination by interview, and a blood test only when it is necessary to evaluate the safety and efficacy of the injection. (*If the subjects performed the screening during the first visit on, the total number of his or her additional visits is four.)
Trial information was received from ClinicalTrials.gov and was last updated in August 2015.
Information provided to ClinicalTrials.gov by Sewon Cellontech Co., Ltd..